


Barclays Wealth Funds

EOS at Federated Hermes

Over the last quarter we made voting recommendations at **242** meetings (**2,384** resolutions). At **118** meetings we recommended opposing one or more resolutions. We recommended voting with management by exception at **nine** meetings. We supported management on all resolutions at the remaining **115** meetings.

Global

We made voting recommendations at **242** meetings (**2,384** resolutions) over the last quarter.



- Total meetings in favour **47.5%**
- Meetings against (or against AND abstain) **48.8%**
- Meetings with management by exception **3.7%**

Australia and New Zealand


We made voting recommendations at **three** meetings (**12** resolutions) over the last quarter.



- Total meetings in favour **66.7%**
- Meetings with management by exception **33.3%**

Developed Asia

We made voting recommendations at **four** meetings (**34** resolutions) over the last quarter.



- Meetings against (or against AND abstain) **100%**

Emerging and Frontier Markets

We made voting recommendations at **91** meetings (**569** resolutions) over the last quarter.



- Total meetings in favour **41.8%**
- Meetings against (or against AND abstain) **56.0%**
- Meetings with management by exception **2.2%**

Europe


We made voting recommendations at **22** meetings (**280** resolutions) over the last quarter.



- Total meetings in favour **40.9%**
- Meetings against (or against AND abstain) **54.5%**
- Meetings with management by exception **4.5%**

North America

We made voting recommendations at **31** meetings (**255** resolutions) over the last quarter.



- Total meetings in favour **12.9%**
- Meetings against (or against AND abstain) **83.9%**
- Meetings with management by exception **3.2%**

United Kingdom

We made voting recommendations at **91** meetings (**1,234** resolutions) over the last quarter.




- Total meetings in favour **68.1%**
- Meetings against (or against AND abstain) **27.5%**
- Meetings with management by exception **4.4%**

The issues on which we recommended voting against management or abstaining on resolutions are shown below.

Global


We recommended voting against or abstaining on **308** resolutions over the last quarter.



- Board structure **49.0%**
- Remuneration **25.3%**
- Shareholder resolution **4.9%**
- Capital structure and dividends **5.2%**
- Amend articles **10.1%**
- Audit and accounts **4.2%**
- Poison pill/Anti-takeover device **0.3%**
- Other **1.0%**

Australia and New Zealand

We recommended voting against or abstaining on **three** resolutions over the last quarter.



- Remuneration **100%**

Developed Asia

We recommended voting against or abstaining on **ten** resolutions over the last quarter.



- Board structure **50%**
- Remuneration **10%**
- Capital structure and dividends **20%**
- Audit and accounts **20%**

Emerging and Frontier Markets

We recommended voting against or abstaining on **160** resolutions over the last quarter.



- Board structure **56.9%**
- Remuneration **14.4%**
- Shareholder resolution **3.8%**
- Capital structure and dividends **5%**
- Amend articles **17.5%**
- Audit and accounts **2.5%**

Europe

We recommended voting against or abstaining on **35** resolutions over the last quarter.



- Board structure **48.6%**
- Remuneration **34.3%**
- Shareholder resolution **2.9%**
- Capital structure and dividends **2.9%**
- Audit and accounts **2.9%**
- Other **8.6%**

North America

We recommended voting against or abstaining on **56** resolutions over the last quarter.



- Board structure **46.4%**
- Remuneration **35.7%**
- Shareholder resolution **12.5%**
- Amend articles **3.6%**
- Audit and accounts **1.8%**

United Kingdom

We recommended voting against or abstaining on **44** resolutions over the last quarter.



- Board structure **27.3%**
- Remuneration **43.2%**
- Shareholder resolution **2.3%**
- Capital structure and dividends **11.4%**
- Amend articles **2.3%**
- Audit and accounts **11.4%**
- Poison pill/Anti-takeover device **2.3%**